Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2026 Earnings Call Transcript May 7, 2026Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock Holding Corp (SRRK)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 10,825,013 | $532,157,639 | 14.75% | |
| 2. | Redmile Group Jeremy Green | 9,066,621 | $445,715,088 | +74% | 29.51% |
| 3. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 6,897,652 | $339,088,572 | 32.95% | |
| 4. | Orbis Investment Management William B. Gray | 4,179,983 | $205,487,964 | +22% | 0.87% |
| 5. | Hood River Capital Management David Swank | 2,049,679 | $100,762,220 | +2% | 1.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.97 | 4,403 | $180,390.91 | 530,038 | 2025-10-07 | Filing | |
| $40.18 | 12,400 | $498,232.00 | 525,635 | 2025-10-07 | Filing | |
| $39.31 | 12,796 | $503,010.76 | 513,235 | 2025-10-07 | Filing | |
| $39.52 | 13,748 | $543,320.96 | 500,439 | 2025-10-06 | Filing | |
| $38.68 | 80,863 | $3,127,780.84 | 486,691 | 2025-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $54.88 | 15 | $823.14 | 27,856 | 2026-07-01 | Filing | |
| $54.24 | 1,470 | $79,727.66 | 27,871 | 2026-07-01 | Filing | |
| $53.53 | 1,568 | $83,939.43 | 29,341 | 2026-07-01 | Filing | |
| $54.81 | 43 | $2,357.02 | 59,511 | 2026-07-01 | Filing | |
| $54.23 | 1,155 | $62,630.68 | 59,554 | 2026-07-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 78,780 | $4,332,900 | 1.38% | |
| 2. | 23,309 | $1,281,995 | 0.03% | |
| 3. | 9,521 | $523,655 | 0.02% | |
| 4. | 3,827 | $210,485 | 0.11% | |
| 5. | 1,406 | $77,330 | 0% |
News See All
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2025 Earnings Call Transcript March 3, 2026Scholar Rock Holding Corporation beats earnings expectations.
Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses
In an announcement last week, Scholar Rock Holding Corp.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2025 Earnings Call Transcript November 14, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress
In an updated report, Scholar Rock Holding Corp.
Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger?
Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD
In the second quarter of the year, Scholar Rock Holding Corp. (NASDAQ:SRRK) saw its net loss widen by 89.6 percent to $110 million from $58 million in the same period last year.
Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss
Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.